Homocysteine is a sulfur-containing amino
|
|
- Hollie Alannah Rose
- 6 years ago
- Views:
Transcription
1 IN THE LITERATURE Approaching the End of the Homocysteine Hype? The following is a commentary on Jamison RL, Hartigan P, Kaufman JS, et al: Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease. A randomized controlled trial. JAMA 298: , Homocysteine is a sulfur-containing amino acid that occupies an important role in 1-carbon metabolism and nucleotide synthesis. Excess homocysteine is exported from the cell and can be measured in plasma. Increased plasma total homocysteine (thcy) concentration is a sensitive marker of folate and cobalamin deficiency. 1 Factors that determine thcy concentration include genetic, physiological, and lifestyle characteristics, as well as various diseases and drugs. In the era of food fortification with folic acid, cobalamin deficiency and impairment of kidney function are the most important determinants of plasma thcy levels. During the last decades, several retrospective and prospective studies showed associations between increased thcy concentrations and increased rates of cardiovascular (CV) events in the general population. 2 However, in patients with chronic kidney disease (CKD), results of prospective studies were inconclusive: some found increased risk of CV outcomes in subjects with greater thcy concentrations, 3 whereas other studies found an inverse association of CV disease (CVD) risk with increasing plasma thcy concentrations 4 or no such associations. 5 However, several experimental studies supported the concept of vascular damage induced by homocysteine and provided yet another rationale for intervention studies aimed at decreasing CV risk through a therapeutic decrease in thcy concentrations. 6 Specifically, clinical trials were designed to provide evidence that thcy-lowering therapy with folic acid and B vitamins may improve CVD outcomes. In the September 12, 2007, issue of the Journal of the American Medical Association, Jamison et al 7 presented such a trial and showed that folic acid, together with vitamin B 6 and vitamin B 12, failed to decrease mortality and CV outcomes in patients with advanced CKD. 7 WHAT DID THIS IMPORTANT STUDY SHOW? In a double-blind, randomized, and controlled multicenter trial (the Homocysteine Study), 2,056 patients aged 21 or older (98% men) from 36 US Department of Veterans Affairs medical centers who had advanced CKD (stages 4, 5, and 5D) and increased thcy concentrations ( 15 mol/l) were randomly assigned to receive either a daily capsule containing 40 mg of folic acid, 100 mg of pyridoxine hydrochloride (vitamin B 6 ), and 2 mg of cyanocobalamin (vitamin B 12 ) or placebo. 7 Recruitment for the study lasted from September 2001 to October 2003, and median follow-up was 3.2 years. A total of 1,024 patients (379 patients with CKD stage 5D, 645 patients with stage CKD 4 or 5) were assigned to placebo, and 1,032 patients (372 patients with CKD stage 5D, 660 patients with CKD stage 4 or 5) were randomly assigned to the vitamin intervention arm. Sample size calculation for that study was based on an estimated 3-year mortality rate of 28% and adjusted for a 7% loss to follow-up. In a population initially supposed to be composed of 78% patients with CKD stage 4 or 5 and 22% patients with CKD stage 5D, 2,006 patients were needed to detect a postulated 17% decrease in all-cause mortality (from 27.9% to 23.2% at 3 years) with statistical power of 80%. Prespecified secondary outcomes included myocardial infarction, stroke, amputation, a composite of death and the 3 aforementioned outcomes, plasma thcy concentrations at 3 months after treatment, and thrombosis of a vascular access in dialysis Address correspondence to Gere Sunder-Plassman, MD, Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, Austria. gere.sunder-plassmann@ meduniwien.ac.at 2008 by the National Kidney Foundation, Inc /08/ $34.00/0 doi: /j.ajkd American Journal of Kidney Diseases, Vol 51, No 4 (April), 2008: pp
2 550 patients. 8 In the published analysis, the investigators also assessed time to initiation of dialysis therapy in patients with CKD stage 4 or 5, not a prespecified end point. In May 2006, the Data and Safety Monitoring Board recommended that the study be stopped because the required number of primary end points had been reached. At 3 months, a significant 26% decrease in plasma thcy concentrations was observed in the intervention group ( 0.8 mg/l [ 6.2 mol/l], from mg/l [ mol/l] at baseline), whereas no significant change was present in the placebo group ( 0.05 mg/l [ 0.4 mol/l], from mg/l [ mol/l] at baseline). In contrast to the thcy-lowering effect of high-dose folic acid and B vitamins, there was no effect of treatment on the primary study end point, allcause mortality (hazard ratio, 1.04; 95% confidence interval [CI], 0.91 to 1.18). Overall, there were 884 deaths: 448 (43.4%) in the intervention group and 436 (42.6%) in the placebo group, representing an annual mortality rate of 11.8% versus 10.0%, respectively. Hazard ratios with 95% CIs for primary and secondary outcomes are listed in Table 1. Sunder-Plassmann, Winkelmayer, and Födinger HOW DOES THIS STUDY COMPARE WITH PRIOR STUDIES? Several other studies of vitamin intervention on homocysteine concentrations in patients with CKD were completed or are underway. Of note, these studies varied considerably in the composition and dose of the vitamin arms. Regarding this, an important study by Bostom et al 9 suggested that increased thcy plasma concentrations in dialysis patients may respond better to greater doses of folic acid (15 mg/d) and B vitamins than usually prescribed in the non-ckd population. More extreme doses of folic acid (30 or 60 mg) had no additional thcy-lowering effect compared with 15 mg in dialysis patients enrolled in The Vienna Multicenter Study. 10 In northern California, Wrone et al 11 randomly assigned 510 patients with CKD stage 5D to receive a multivitamin together with different doses of folic acid, but a placebo group was not included. During a median follow-up of 2 years, patients randomly assigned to receive 5 or 15 mg/d of folic acid experienced similar rates of mortality, CV events, and access thrombosis compared with those who received 1 mg of folic acid. 11 The Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in Chronic Renal Failure 12 randomly assigned 315 patients (CKD stages 4, 5, and 5D) to 15 mg of folic acid or placebo and failed to show an effect on progression of carotid artery intima-media thickness (difference, 0.01 mm/y; CI, 0.01 to 0.03; P 0.4) or the incidence of CV events (hazard ratio, 0.98; 95% CI, 0.66 to 1.47) after a median observation time of 3.6 years. 12 Most recently, Mann et al 13 presented data from a secondary analysis of the Heart Outcomes Prevention Evaluation (HOPE)-2 trial. In that trial, 5,522 high-risk patients were randomly assigned to receive a daily combination pill containing folic acid, 2.5 mg; vitamin B 6,50mg; and vitamin B 12, 1 mg or placebo. In 3,310 patients randomly selected from the full study population, serum samples were collected and Table 1. Primary and Secondary Outcomes of the Homocysteine Study No. (%) of Patients With an Event Vitamin Group (n 1,032) Placebo Group (n 1,024) Hazard Ratio (95% CI) P All-cause mortality 448(43) 436 (43) 1.04 ( ) 0.6 Myocardial infarction (fatal and nonfatal) 129 (13) 150 (15) 0.86 ( ) 0.2 Stroke (fatal and nonfatal) 37 (4) 41 (4) 0.90 ( ) 0.6 Amputation 60 (6) 53 (5) 1.14 ( ) 0.5 Composite 523 (51) 525 (51) 0.99 ( ) 0.9 Dialysis in CKD stage 4 or (55) 340 (53) 1.07 ( ) 0.4 Access thrombosis in CKD stage 5D 166 (24) 163 (23) 1.01 ( ) 0.97 Abbreviation: CKD, chronic kidney disease. Adapted with permission from Jamison et al. 7
3 In the Literature 551 Table 2. Results of Total Homocysteine Lowering Trials in the General Population Study, Reference, Journal, Year No. of Patients Outcome Trial Duration Risk/Hazard Ratio (95% confidence interval) IMPROVEMENT WITH INTERVENTION Swiss Heart Study, 17 N Engl J Med, Coronary restenosis after PTCA 6 mo 0.52 ( ) Swiss Heart Study, 18 JAMA, MACE after PTCA 1 y 0.68 ( ) FACIT, 19 Lancet, 2007* 818 Memory (change in z score) 3 y ( ) NO EFFECT OF INTERVENTION Liem et al, 20 J Am Coll Cardiol, Mortality & CVD events 2 y 1.05 ( ) VISP, 21 JAMA, ,680 Recurrent stroke 2 y 1.0 ( ) McMahon et al, 22 N Engl J Med, Cognitive function (combined score) 2 y 0.11 ( 0.2-0) HOPE-2, 23 N Engl J Med, ,522 CVD death, MI, stroke 5 y 0.95 ( ) HOPE-2, 24 Ann Intern Med, ,522 Venous thromboembolism 5 y 1.01 ( ) VITRO, 25 Blood, Recurrent venous thromboembolism 2.5 y 0.84 ( ) WORSE OUTCOME WITH INTERVENTION Lange et al, 26 N Engl J Med, In-stent restenosis 6 mo 1.30 ( ) NORVIT, 27 N Engl J Med, ,749 MACE after MI 40 mo 1.22 ( ) Abbreviations: PTCA, percutaneous transluminal coronary angioplasty; MACE, major adverse cardiovascular events; CVD, cardiovascular disease; MI, myocardial infarction; CVD, cardiovascular disease; FACIT, Folic Acid and Carotid-Intimamedia Thickness trial; VISP, Vitamin Intervention for Stroke Prevention; HOPE, Heart Outcomes Prevention Evaluation; VITRO, Vitamins and Thrombosis study; NORVIT, Norwegian Vitamin trial. *Secondary analysis, primary results not reported. Secondary analysis. serum creatinine was measured in a central laboratory. A total of 619 patients had an estimated glomerular filtration rate less than 60 ml/min/ 1.73 m 2 ( 1 ml/s/1.73 m 2 ) and were included in this post hoc analysis. After a median observation time of 5 years, active treatment did not decrease the risk of the primary outcome (composite of death from CVD, myocardial infarction, and stroke; relative risk, 1.19; 95% CI, 0.88 to 1.61; P 0.2), but increased the risk of hospitalization for heart failure (relative risk, 1.98; 95% CI, 1.21 to 3.26; P 0.007) or unstable angina (relative risk, 1.70; 95% CI, 1.02 to 2.83; P 0.04). 13 Enrollment for some other large thcy-lowering studies (Folic Acid for Vascular Outcome Reduction In Transplantation [FAVORIT] trial study population, 4,000 kidney transplant recipients 14 ); the Prospective Intervention Study from Magdeburg With Vitamins (PRISMAVIT) trial (study population, 650 patients with CKD stage 5D; Jutta Dierkes, Germany, personal communication, October 2007); the Vitamins To Prevent Stroke (VITATOPS) trial (study population, 8,000 patients with cerebrovascular disease 15 ); the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH; study population, 12,064 myocardial infarction survivors 16 ) was completed recently, and their results are being awaited with interest. Until now, only 1 study in the general population suggested a beneficial effect of folic acid and vitamin intervention on CVD outcomes (Table 2). All other studies showed no such effect or even worse outcomes in the intervention group. Thus, the lack of effect of thcy-lowering therapies in the general population (Table 2), as well as the negative results of the hitherto published studies in patients with CKD, do not suggest that the yet uncompleted studies will show a major effect of thcy-lowering interventions on CVD outcomes. WHAT SHOULD CLINICIANS AND RESEARCHERS DO? From the clinical point of view, thcy-lowering therapy can be considered to have no major effect on important CVD or kidney disease outcomes. Nevertheless, some experts in the field have claimed that one should not yet abandon the Hcy pathway for potential interventions aimed at curbing CV risk. 4 Our recommendation is more conservative. Folic acid alone can mask the megaloblastic anemia caused by cobalamin deficiency and thereby permit neurological dysfunction to
4 552 develop and sometimes become irreversible. 28 In addition, some of the aforementioned thcylowering trials in the general population, as well as in patients with CKD, even showed an increased risk of CV outcomes in patients treated with folic acid and B vitamins compared with those administered placebo (Table 2 and 13 ). We therefore do not support the opinion that decreasing homocysteine concentrations in patients with CKD is important even in the absence of trials showing the benefit of such intervention. In summary, at present, no evidence is available that supports the concept of thcy-lowering intervention with folic acid and B vitamins to improve CVD outcomes in the general population or patients with CKD. The study of Jamison et al 7 is yet another contribution to the growing number of large randomized intervention trials that failed to show improved outcomes in patients with CKD Thus, prevention of CKD per se moves to center stage and should have top priority on the research agenda. Gere Sunder-Plassmann, MD Medical University Vienna Vienna, Austria Wolfgang C. Winkelmayer, MD, ScD Harvard Medical School Boston, Massachusetts Manuela Födinger, MD Medical University Vienna Vienna, Austria ACKNOWLEDGEMENTS Support: None. Financial Disclosure: None. REFERENCES 1. Refsum H, Smith AD, Ueland PM, et al: Facts and recommendations about total homocysteine determinations: An expert opinion. Clin Chem 50:3-32, The Homocysteine Studies Collaboration: Homocysteine and risk of ischemic heart disease and stroke. A meta-analysis. JAMA 288: , Winkelmayer WC, Kramar R, Curhan GC, et al: Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: A prospective study. J Am Soc Nephrol 16: , Zoccali C, Mallamaci F, Tripepi G: It is important to lower homocysteine in dialysis patients. Semin Dial 20: , 2007 Sunder-Plassmann, Winkelmayer, and Födinger 5. Menon V, Sarnak MJ, Greene T, et al: Relationship between homocysteine and mortality in chronic kidney disease. Circulation 113: , Loscalzo J: The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 98:5-7, Jamison RL, Hartigan P, Kaufman JS, et al: Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: A randomized controlled trial. JAMA 298: , Jamison RL, Hartigan P, Gaziano JM, et al: Design and statistical issues in the homocysteinemia in kidney and end stage renal disease (HOST) study. Clin Trials 1: , Bostom AG, Shemin D, Lapane KL, et al: High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 49: , Sunder-Plassmann G, Födinger M, Buchmayer H, et al: Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: Results of the Vienna Multicenter Study. J Am Soc Nephrol 11: , Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP: Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 15: , Zoungas S, McGrath BP, Branley P, et al: Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in Chronic Renal Failure: A multicenter, randomized, controlled trial. J Am Coll Cardiol 47: , Mann JF, Sheridan P, McQueen MJ, et al: Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease: Results of the renal HOPE-2 Study. Nephrol Dial Transplant 23: , Bostom AG, Carpenter MA, Kusek JW, et al: Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial. Am Heart J 152:e441-e448, The VITATOPS (Vitamins to Prevent Stroke) Trial: Rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis 13: , Bowman L, Armitage J, Bulbulia R, Parish S, Collins R: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH): Characteristics of a randomized trial among myocardial infarction survivors. Am Heart J 154: , Schnyder G, Roffi M, Pin R, et al: Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 345: , Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM: Effect of homocysteine-lowering therapy with folic acid, vitamin B 12, and vitamin B 6 on clinical outcome after percutaneous coronary intervention: The Swiss Heart Study: A randomized controlled trial. JAMA 288: , Durga J, van Boxtel MP, Schouten EG, et al: Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: A randomised, double blind, controlled trial. Lancet 369: , 2007
5 In the Literature Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ: Secondary prevention with folic acid: Effects on clinical outcomes. J Am Coll Cardiol 41: , Toole JF, Malinow MR, Chambless LE, et al: Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291: , McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM: A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 354: , Lonn E, Yusuf S, Arnold MJ, et al: Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354: , Ray JG, Kearon C, Yi Q, Sheridan P, Lonn E: Homocysteine-lowering therapy and risk for venous thromboembolism: A randomized trial. Ann Intern Med 146: , den Heijer M, Willems HP, Blom HJ, et al: Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood 109: , Lange H, Suryapranata H, De Luca G, et al: Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 350: , Bonaa KH, Njolstad I, Ueland PM, et al: Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354: , Dhar M, Bellevue R, Carmel R: Pernicious anemia with neuropsychiatric dysfunction in a patient with sickle cell anemia treated with folate supplementation. N Engl J Med 348: , Klahr S, Levey AS, Beck GJ, et al: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330: , Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: , Eknoyan G, Beck GJ, Cheung AK, et al: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347: , Holdaas H, Fellstrom B, Jardine AG, et al: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 361: , Wanner C, Krane V, März W, et al: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: , Singh AK, Szczech L, Tang KL, et al: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: , Suki WN, Zabaneh R, Cangiano JL, et al: Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72: , 2007
The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationFolate and prevention of neural tube defects: Tracking red blood cell concentrations will help guide policy decisions about fortification
Folate and prevention of neural tube defects: Tracking red blood cell concentrations will help guide policy decisions about fortification Derrick Bennett, University of Oxford, UK 8 October, 2014 IXth
More informationReview Article The association between B vitamins supplementation and adverse cardiovascular events: a meta-analysis
Int J Clin Exp Med 2014;7(8):1923-1930 www.ijcem.com /ISSN:1940-5901/IJCEM0001191 Review Article The association between B vitamins supplementation and adverse cardiovascular events: a meta-analysis Wen-Feng
More informationAppendix 1 Characteristics of Trials Included in the Final Meta-Analysis (n = 50) [posted as supplied by author] Duration of Supplementa
Appendix 1 Characteristics of Trials Included in the Final Meta-Analysis (n = 50) [posted as supplied by author] Duration of Supplementa Participants tion, y (Average Age, y; (Follow-up Intervention vs.
More informationTitle: Statins for haemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D study.
Manuscript type: Invited Commentary: Title: Statins for haemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D study. Authors: David C Wheeler 1 and Bertram
More informationAlthough a number of prospective observational studies. Vascular Medicine
Vascular Medicine B Vitamins and the Risk of Total Mortality and Cardiovascular Disease in End-Stage Renal Disease Results of a Randomized Controlled Trial Judith Heinz, MSc; Siegfried Kropf, PhD; Ute
More informationFolic Acid Therapy and Cardiovascular Disease in ESRD or Advanced Chronic Kidney Disease: A Meta- Analysis
Article Folic Acid Therapy and Cardiovascular Disease in ESRD or Advanced Chronic Kidney Disease: A Meta- Analysis Xianhui Qin,* Yong Huo, Craig B. Langman, Fanfan Hou, Yundai Chen, Debora Matossian, Xiping
More informationSevere hyperhomocysteinemia, a feature of inborn errors
Efficacy of Homocysteine-Lowering Therapy With Folic Acid in Stroke Prevention A Meta-Analysis Meng Lee, MD; Keun-Sik Hong, MD, PhD; Shen-Chih Chang, PhD; Jeffrey L. Saver, MD Background and Purpose Although
More informationAPPENDIX A NORTH AMERICAN SYMPTOMATIC CAROTID ENDARTERECTOMY TRIAL
APPENDIX A Primary Findings From Selected Recent National Institute of Neurological Disorders and Stroke-Sponsored Clinical Trials That Have shaped Modern Stroke Prevention Philip B. Gorelick 178 NORTH
More informationClinical Policy: Homocysteine Testing Reference Number: CP.MP.121
Clinical Policy: Reference Number: CP.MP.121 Effective Date: 08/16 Last Review Date: 08/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationMcCully postulated in 1969 that homocysteine affected
Folic Acid Supplementation and the Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials Yanping Li, PhD; Tianyi Huang, ScD; Yan Zheng, PhD; Tauland Muka, PhD; Jenna Troup, MPH;
More informationPage: 1 of 11. Homocysteine Testing in the Screening, Diagnosis and Management of Cardiovascular Disease
Last Review Status/Date: June 2015 Page: 1 of 11 Diagnosis and Management of Description Homocysteine is an amino acid found in the blood; levels are inversely correlated with folate levels. Homocysteine
More information( 1) Framingham Heart
( 1) ( 1) Framingham Heart Study [1] 1. (Am J Kidney Dis. 45: 223-232, 2005) 96 19 1 17 Framingham Heart Study ( 1) American Heart Association (1) (2) (3) (4) [2] (GFR) [3] ARIC [4] Cardiovascular Health
More informationInterventions for lowering plasma homocysteine levels in dialysis patients (Review)
Charles Darwin University Nigwekar, Sagar; Kang, Amy; Zoungas, Sophia; Cass, Alan; Gallagher, Martin; Kulshrestha, Satyarth; Navaneethan, Sankar; Perkovic, Vlado; Strippoli, Giovanni; Jardine, Meg Published
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: April 15, 2017 Related Policies: None Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease and Venous Thromboembolic Disease
More informationHomocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease and Venous Thromboembolic Disease
Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease and Venous Thromboembolic Disease Policy Number: 2.04.23 Last Review: 07/2017 Origination: 07/2015 Next Review:
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationIndependent Risk Factors of Cardiovascular Disease Achieving Healthy Homocysteine Levels
Independent Risk Factors of Cardiovascular Disease Achieving Healthy Homocysteine Levels AUTHORS: JON LEGERE, BRADLEY RALPH, DR. RON LEGERE 15344 N 83RD WAY, SCOTTSDALE, AZ 85260 TEL: 800.528.3144 EMAIL:
More informationHomocysteine Testing Corporate Medical Policy
File name: Homocysteine Testing File code: UM.DIAG.02 Origination: 1/2011 Last Review 06/2017 Next Review: 06/2018 Effective Date: 11/01/2017 Homocysteine Testing Corporate Medical Policy Description Homocysteine
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationStatins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.
More informationMedical Coverage Policy Homocysteine Testing in the Screening and Diagnosis and Management of Cardiovascular Disease
Medical Coverage Policy Homocysteine Testing in the Screening and Diagnosis and Management of Cardiovascular Disease EFFECTIVE DATE:05 02 2017 POLICY LAST UPDATED:10 02 2018 OVERVIEW Homocysteine is an
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationChapter 8. M den Heijer, HPJ Willems, HJ Blom, WBJ Gerrits, M Cattaneo, S Eichinger, FR Rosendaal, GMJ Bos. Blood 2006 Sep 7 [Epub ahead of print]
Chapter 8 Homocysteine lowering by B vitamins and the secondary prevention of deep-vein thrombosis and pulmonary embolism. A randomized, placebo-controlled, double blind trial M den Heijer, HPJ Willems,
More informationHomocysteine Hypothesis for Atherothrombotic Cardiovascular Disease Not Validated
Journal of the American College of Cardiology Vol. 48, No. 5, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.04.086
More informationChapter 2: Pharmacological cholesterol-lowering treatment in adults Kidney International Supplements (2013) 3, ; doi: /kisup.2013.
http://www.kidney-international.org chapter & 3 KDIGO Chapter : Pharmacological cholesterol-lowering treatment in adults Kidney International Supplements (3) 3, 7 79; doi:.38/kisup.3.34 INTRODUCTION Therapeutic
More informationLIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
More informationRandomized Trial of Folic Acid for Prevention of Cardiovascular Events in End-Stage Renal Disease
Randomized Trial of Folic Acid for Prevention of Cardiovascular Events in End-Stage Renal Disease J Am Soc Nephrol 15: 420 426, 2004 ELIZABETH M. WRONE,* JOHN M. HORNBERGER, JAMES L. ZEHNDER, LINDA M.
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationThe use of surrogates as key performance indicators
REPLY The use of surrogates as key performance indicators Dr José Vinhas Department of Nephrology, Centro Hospitalar de Setúbal. Setúbal, Portugal Received for publication: 24/08/2012 Accepted: 31/08/2012
More informationThe earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College
The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationThe role of vitamins in stroke prevention has been studied
Emerging Therapy Critiques The Role of Vitamin B in Stroke Prevention A Journey From Observational Studies to Clinical Trials and Critique of the VITAmins TO Prevent Stroke (VITATOPS) Gustavo Saposnik,
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationLEADER Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect
More informationHOMOCYSTEINE LEVELS HAVE
ORIGINAL CONTRIBUTION Effect of Folic Acid and B Vitamins on Risk of Cardiovascular Events and Total Mortality Among Women at High Risk for Cardiovascular Disease A Randomized Trial Christine M. Albert,
More informationThe Seventh Report of the Joint National Commission
The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study Mark J. Sarnak, MD; Tom Greene, PhD; Xuelei Wang,
More informationAmong the determinants and correlates of total plasma
Genetic Aspects of Hyperhomocysteinemia in Chronic Kidney Disease Gere Sunder-Plassmann, Wolfgang C. Winkelmayer, and Manuela Födinger Patients with chronic kidney disease who are on dialysis or with a
More informationFolate, vitamin B 6, and vitamin B 12 are cofactors in
Research Letters Dietary Folate and Vitamin B 6 and B 12 Intake in Relation to Mortality From Cardiovascular Diseases Japan Collaborative Cohort Study Renzhe Cui, MD; Hiroyasu Iso, MD; Chigusa Date, MD;
More informationHomocysteine Testing in the Screening, Diagnosis and Management of Cardiovascular Disease Corporate Medical Policy
Homocysteine Testing in the Screening, Diagnosis and Management of Cardiovascular Disease Corporate Medical Policy File name: Homocysteine Testing in the Screening, Diagnosis and Management of Cardiovascular
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More informationEchocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More informationHORMONE REPLACEMENT THERAPY
TRIALS OF HR RUTH (Barrett- Connor et al 29 ) JULY 2006 (Country) mean ± sd, range International trial 67.5 an Placebo component in 67.5 ± 6.7 women with Raloxifene or multiple 67.5 ± 6.6 risk factors
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationJ. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018
ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events): A Study to Assess the Efficacy and Safety of Aspirin in Patients at Moderate Risk of Cardiovascular Disease J. Michael Gaziano, M.D., M.P.H.
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationSYNOPSIS. Issue Date: 04 February 2009 Document No.: EDMS -USRA
SYNOPSIS Issue Date: 04 February 2009 Document No.: EDMS -USRA-10751204 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Johnson & Johnson Pharmaceutical Research & Development,
More informationN Engl J Med 2018;378: DOI: /NEJMoa Lin, Wan-Ting 2018/06/27
N Engl J Med 2018;378:1200-10. DOI: 10.1056/NEJMoa1710895 Lin, Wan-Ting 2018/06/27 1 Introduction Gout is a chronic illness characterized by hyperuricemia, arthropathy, tophus development, and urolithiasis
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationCHOLESTEROL-LOWERING THERAPHY
CHOLESTEROL-LOWERING THERAPHY TRIALS NUMBER OF PARTICIPANTS NUMBER OF WOMEN PERCENTAGE OF WOMEN MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 50,194 15,036 30.0% 60.8 3.2 1/ 6 (16.7%) HR
More informationFolic Acid in Stroke Prevention in Countries without Mandatory Folic Acid Food Fortification: A Meta-Analysis of Randomized Controlled Trials
Journal of Stroke 2018;20(1):99-109 https://doi.org/10.5853/jos.2017.01522 Original Article Folic Acid in Stroke Prevention in Countries without Mandatory Folic Acid Food Fortification: A Meta-Analysis
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationJoshua A. Beckman, MD. Brigham and Women s Hospital
Peripheral Vascular Disease: Overview, Peripheral Arterial Obstructive Disease, Carotid Artery Disease, and Renovascular Disease as a Surrogate for Coronary Artery Disease Joshua A. Beckman, MD Brigham
More informationA Randomized Trial of a Multivitamin (MVM) in the Prevention of Cardiovascular Disease in Men: The Physicians Health Study (PHS) II
A Randomized Trial of a Multivitamin (MVM) in the Prevention of Cardiovascular Disease in Men: The Physicians Health Study (PHS) II Presenter Disclosure Information Howard D. Sesso, ScD, MPH Relevant Disclosures:
More informationContrast Induced Nephropathy
Contrast Induced Nephropathy O CIAKI refers to an abrupt deterioration in renal function associated with the administration of iodinated contrast media O CIAKI is characterized by an acute (within 48 hours)
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationCardiovascular Mortality: General Population vs ESRD Dialysis Patients
Cardiovascular Mortality: General Population vs ESRD Dialysis Patients Annual CVD Mortality (%) 100 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age (years) GP Male GP Female GP Black GP
More informationBlood Pressure Treatment Goals
Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More information03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE
CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE Elizabeth L. Detschelt, M.D. Allegheny Health Network Vascular and Endovascular Symposium April 2, 2016 DISCLOSURES I have no
More information1. What is the preferred method of anticoagulating a high-risk cardiac patient on chronic warfarin therapy. anticoagulation can be continued,
Experts Answering Your Questions Anticoagulating a high-risk cardiac patient 1. What is the preferred method of anticoagulating a high-risk cardiac patient on chronic warfarin therapy for minor surgical
More informationBayer s rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery disease
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s rivaroxaban submitted to U.S. FDA for approval in patients with coronary
More informationImpact of Serum Homocysteine on Platelet Count in Stable Hemodialysis Patients
Impact of Serum Homocysteine on Platelet Count in Stable Hemodialysis Patients Hamid Nasri, MD Hemodialysis Section, Hajar Medical, Educational and Therapeutic Center, Shahrekord University of Medical
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationEffect of SGLT-2 Inhibitors on the Heart. Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic
Effect of SGLT-2 Inhibitors on the Heart Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic Disclosures Speaker - Johnson and Johnson - Merck Research - Merck - Novo
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationOBSERVATIONAL STUDIES
ORIGINAL CONTRIBUTION Effects of Homocysteine-Lowering With Folic Acid Plus Vitamin B 12 vs on Mortality and Major Morbidity in Myocardial Infarction Survivors A Randomized Trial Study of the Effectiveness
More informationHypertension is an important global public
IN THE LITERATURE Blood Pressure Target in Individuals Without Diabetes: What Is the Evidence? Commentary on Verdecchia P, Staessen JA, Angeli F, et al; on behalf of the Cardio-Sis Investigators. Usual
More informationHypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF
Hypertension: What s new since JNC 7 Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Disclosures Spectral Diagnostics Site investigator Eli Lilly Site investigator ACP IM ITE writing committee NBME Step
More informationSupplementary Online Content
Supplementary Online Content Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationThis review is contributed by Professor Helene McNulty RD and Dr Mary Ward RD from the University of Ulster, Northern Ireland.
1.1.1 Folate This review is contributed by Professor Helene McNulty RD and Dr Mary Ward RD from the University of Ulster, Northern Ireland. 1.1.1.1 Summary In recent years there has been much interest
More informationFelix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCARDIO-RENAL SYNDROME
CARDIO-RENAL SYNDROME Luis M Ruilope Athens, October 216 DISCLOSURES: ADVISOR/SPEAKER for Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Esteve, GSK Janssen, Lacer, Medtronic, MSD, Novartis, Pfizer, Relypsa,
More informationΣυμπεράσματα από τις νέες μελέτες για την αρτηριακή υπέρταση (SPRINT,PATHAY 2,HOPE 3)
Συμπεράσματα από τις νέες μελέτες για την αρτηριακή υπέρταση (SPRINT,PATHAY 2,HOPE 3) Χάρης Γράσσος MD,FESC,PhD,EHS Διευθυντής Καρδιολόγος Γ.Ν.Α ΚΑΤ Visiting Professor University of Bolton U.K New England
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationHealth technology Abciximab use in high-risk patients undergoing percutaneous transluminal coronary angioplasty.
Costs and effects in therapy for acute coronary syndromes: the case of abciximab in highrisk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study van Hout B A, Bowman L,
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationIn the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi
Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.
More information